OQS
DNLI icon

Occudo Quantitative Strategies’s Denali Therapeutics DNLI Stock Holding History

Occudo Quantitative Strategies’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-29,221
Closed -$673K – 1072
2023
Q1 		$673K Buy
+29,221
New +$804K 0.06% 425
2022
Q3 		– Sell
-10,672
Closed -$314K – 1242
2022
Q2 		$314K Buy
+10,672
New +$280K 0.03% 776
2021
Q1 		– Sell
-12,589
Closed -$1.05M – 794
2020
Q4 		$1.05M Buy
+12,589
New +$761K 0.33% 55

Other funds holding DNLI

Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
CM
Crestline Management Fort Worth, Texas $53.5M AUM 80.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return
FP
Flagship Pioneering Cambridge, Massachusetts $1.54B AUM 86.39% 1-Year Est. Return

Occudo Quantitative Strategies's DNLI Position: Q2 2023 in Review

Occudo Quantitative Strategies sold out of Denali Therapeutics (DNLI) in Q2 2023, closing a stake of 29,221 shares — an estimated $673K sold.

Occudo Quantitative Strategies first reported a position in DNLI in Q4 2020 and held it in 3 quarters. The position peaked at $1.05M in Q4 2020. 203 funds tracked by Wall St. Rank hold DNLI as of Q2 2023.

  • Occudo Quantitative Strategies reported no remaining Denali Therapeutics position as of Q2 2023 after selling out during the quarter.
  • Occudo Quantitative Strategies sold 29,221 Denali Therapeutics shares in Q2 2023, an estimated $673K.
  • Occudo Quantitative Strategies first reported a position in Denali Therapeutics in Q4 2020 and held it in 3 quarters.
  • Occudo Quantitative Strategies's Denali Therapeutics position peaked at $1.05M in Q4 2020.
  • 203 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2023.

Based on Occudo Quantitative Strategies's 13F filing for Q2 2023, filed 14 Aug 2023.